Alligator’s Mitazalimab Shows Promise in Pancreatic Cancer Treatment

Introduction

Alligator Bioscience, a Sweden-based biotech company, recently presented promising results from its Phase II readout of mitazalimab, a monoclonal antibody, in combination with mFOLFIRINOX chemotherapy for the treatment of pancreatic cancer. The data was published in the Lancet Oncology on June 3, 2024, and the study showed an improvement over historical data for patients with metastatic pancreatic cancer.

Promising Results

Patients who received mitazalimab with mFOLFIRINOX demonstrated a confirmed Objective Response Rate (ORR) of 40.4% and a median overall survival (mOS) of 14.3 months, compared to the historical ORR of 31.6% and mOS of 11.1 months. Alligator CEO Dr. Søren Bregenholt said adding three months to the mOS is clinically meaningful, especially since pancreatic cancer patients have few treatment options.

The Need for Better Pancreatic Cancer Treatments

Pancreatic cancer patients have limited treatment options, with chemotherapy being the primary treatment option for 80% of patients. Approved therapies have shown to have a mediocre response rate and limited clinical benefit, making the need for new treatments crucial. In February 2024, the US Food and Drug Administration (FDA) approved Ipsen Biopharmaceuticals’ chemotherapy combination, NALIRIFOX, for the first-line treatment of pancreatic cancer. NALIRIFOX uses Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil, and leucovorin to treat the disease.

Comparing Treatment Options

According to Bregenholt, the treatment with mitazalimab has very few adverse reactions and side effects compared to the many commonly associated with other marketed chemotherapy combinations. With the promising results from the Phase II readout, Alligator plans to initiate a Phase III trial in the first half of next year.

Conclusion

Mitazalimab in combination with chemotherapy has shown promise in improving the overall survival of pancreatic cancer patients, providing hope for those with limited treatment options. Alligator’s goal is to provide a more effective and less toxic alternative to traditional chemotherapy treatments. The Phase III trial next year will provide further insight into the effectiveness of mitazalimab as a pancreatic cancer treatment option.

Long-tail Keywords:

– Mitazalimab and pancreatic cancer treatment
– Alligator Bioscience Phase II readout
– Monoclonal antibody treatments
– mFOLFIRINOX chemotherapy
– Limited treatment options for pancreatic cancer
– New pancreatic cancer treatment options

Originally Post From https://www.pharmaceutical-technology.com/news/asco-2024-alligator-shares-positive-data-for-pancreatic-cancer-drug/

Alligator Delivers Promising Pancreatic Cancer Drug Results at ASCO 2024